全文获取类型
收费全文 | 1044篇 |
免费 | 65篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 24篇 |
妇产科学 | 10篇 |
基础医学 | 214篇 |
口腔科学 | 4篇 |
临床医学 | 69篇 |
内科学 | 545篇 |
皮肤病学 | 42篇 |
神经病学 | 48篇 |
特种医学 | 2篇 |
外科学 | 20篇 |
综合类 | 28篇 |
预防医学 | 70篇 |
眼科学 | 3篇 |
药学 | 19篇 |
肿瘤学 | 10篇 |
出版年
2023年 | 7篇 |
2022年 | 1篇 |
2021年 | 6篇 |
2020年 | 1篇 |
2018年 | 23篇 |
2017年 | 15篇 |
2016年 | 22篇 |
2015年 | 26篇 |
2014年 | 19篇 |
2013年 | 33篇 |
2012年 | 95篇 |
2011年 | 119篇 |
2010年 | 31篇 |
2009年 | 18篇 |
2008年 | 106篇 |
2007年 | 107篇 |
2006年 | 79篇 |
2005年 | 63篇 |
2004年 | 104篇 |
2003年 | 85篇 |
2002年 | 50篇 |
2001年 | 59篇 |
2000年 | 13篇 |
1999年 | 4篇 |
1998年 | 8篇 |
1997年 | 3篇 |
1996年 | 2篇 |
1995年 | 1篇 |
1994年 | 4篇 |
1993年 | 2篇 |
1992年 | 2篇 |
1989年 | 1篇 |
排序方式: 共有1109条查询结果,搜索用时 15 毫秒
71.
72.
Caroline A Sabin Teresa Hill Fiona Lampe Ryanne Matthias Sanjay Bhagani Richard Gilson Mike S Youle Margaret A Johnson Martin Fisher George Scullard Philippa Easterbrook Brian Gazzard Andrew N Phillips on behalf of the steering committee UK Collaborative HIV Cohort Study Group 《British medical journal》2005,330(7493):695
73.
74.
Quirino T Niero F Ricci E Pusterla L Carradori S Gabbuti A Iemoli E Landonio S Faggion I Bonfanti P;CISAI study group. Italian Coordination for the Study HIV Infection Allergies 《Antiviral therapy》2000,5(3):195-197
The aim of our study is to compare the tolerability of zidovudine/lamivudine/indinavir when used in post-exposure prophylaxis (PEP) subjects and in HIV-infected patients. HIV-negative patients were enrolled as part of the surveillance protocol for professional exposure at the Luigi Sacco Hospital in Milan. HIV-positive patients were selected among all subjects undergoing treatment with zidovudine/lamivudine/indinavir from the CISAI cohort, an Italian cohort for the evaluation of adverse reactions to HAART. In both studies patients were followed prospectively and the severity of the reactions was evaluated using the AIDS Clinical Trial Group adverse experience grading scales. Up to September 1999, 37 HIV-seronegative subjects had undergone treatment with zidovudine/ lamivudine/indinavir. From a total of 1207 patients belonging to the CISAI cohort, 199 were identified as being treated with the same regimen. The frequency of adverse events in the PEP subjects was 70.3% compared to 11.1% for HIV-infected patients. In the first group, adverse events caused treatment interruption in 21 subjects (56.7%) versus 14 patients (7%) among the HIV-infected group. Only one case of a severe event (grade 3-4) was observed in the prophylaxis group against 12 in the treatment group. Our study shows that treatment interruption is eight times higher in HIV-negative subjects compared to HIV-seropositive patients, and that the incidence of adverse events is approximately six times higher, though such events, are for the most part, not severe. 相似文献
75.
Direct‐acting antivirals are effective and safe in HCV/HIV‐coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study
下载免费PDF全文
![点击此处可从《American journal of transplantation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Christian Manzardo Maria C. Londoño LLuís Castells Milagros Testillano José Luis Montero Judit Peñafiel Marta Subirana Ana Moreno Victoria Aguilera María Luisa González‐Diéguez Jorge Calvo‐Pulido Xavier Xiol Magdalena Salcedo Valentin Cuervas‐Mons José Manuel Sousa Francisco Suarez Trinidad Serrano Jose Ignacio Herrero Miguel Jiménez José R. Fernandez Carlos Giménez Santos del Campo Juan I. Esteban‐Mur Gonzalo Crespo Asunción Moreno Gloria de la Rosa Antoni Rimola Jose M. Miro and the FIPSE LT‐HIV investigators 《American journal of transplantation》2018,18(10):2513-2522
Direct‐acting antivirals have proved to be highly efficacious and safe in monoinfected liver transplant (LT) recipients who experience recurrence of hepatitis C virus (HCV) infection. However, there is a lack of data on effectiveness and tolerability of these regimens in HCV/HIV‐coinfected patients who experience recurrence of HCV infection after LT. In this prospective, multicenter cohort study, the outcomes of 47 HCV/HIV‐coinfected LT patients who received DAA therapy (with or without ribavirin [RBV]) were compared with those of a matched cohort of 148 HCV‐monoinfected LT recipients who received similar treatment. Baseline characteristics were similar in both groups. HCV/HIV‐coinfected patients had a median (IQR) CD4 T‐cell count of 366 (256‐467) cells/µL. HIV‐RNA was <50 copies/mL in 96% of patients. The DAA regimens administered were SOF + LDV ± RBV (34%), SOF + SMV ± RBV (31%), SOF + DCV ± RBV (27%), SMV + DCV ± RBV (5%), and 3D (3%), with no differences between the groups. Treatment was well tolerated in both groups. Rates of SVR (negative serum HCV‐RNA at 12 weeks after the end of treatment) were high and similar for coinfected and monoinfected patients (95% and 94%, respectively; P = .239). Albeit not significant, a trend toward lower SVR rates among patients with advanced fibrosis (P = .093) and genotype 4 (P = .088) was observed. In conclusion, interferon‐free regimens with DAAs for post‐LT recurrence of HCV infection in HIV‐infected individuals were highly effective and well tolerated, with results comparable to those of HCV‐monoinfected patients. 相似文献
76.
77.
78.
Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study 总被引:1,自引:0,他引:1
Simcock M Blasko M Karrer U Bertisch B Pless M Blumer L Vora S Robinson JO Bernasconi E Terziroli B Moirandat-Rytz S Furrer H Hirschel B Vernazza P Sendi P Rickenbach M Bucher HC Battegay M Koller MT;Swiss HIV Cohort Study 《Antiviral therapy》2007,12(6):931-939
OBJECTIVE: To assess the characteristics of combination antiretroviral therapy (cART) administered concomitantly with chemotherapy and to establish prognostic determinants of patients with AIDS-related non-Hodgkin's lymphoma. METHODS: The study included 91 patients with AIDS-related non-Hodgkin's lymphoma from the Swiss HIV Cohort Study enrolled between January 1997 and October 2003, excluding lymphomas of the brain. We extracted AIDS-related non-Hodgkin's lymphoma- and HIV-specific variables at the time of lymphoma diagnosis as well as treatment changes over time from charts and from the Swiss HIV Cohort Study database. Cox regression analyses were performed to study predictors of overall and progression-free survival. RESULTS: During a median follow up of 1.6 years, 57 patients died or progressed. Thirty-five patients stopped chemotherapy prematurely (before the sixth cycle) usually due to disease progression; these patients had a shorter median survival than those who completed six or more cycles (14 versus 28 months). Interruptions of cART decreased from 35% before chemotherapy to 5% during chemotherapy. Factors associated with overall survival were CD4+ T-cell count (<100 cells/microl) (hazard ratio [HR] 2.95 [95% confidence interval (CI) 1.53-5.67], hepatitis C seropositivity (HR 2.39 [95% CI 1.01-5.67]), the international prognostic index score (HR 1.98-3.62 across categories) and Burkitt histological subtypes (HR 2.56 [95% CI 1.13-5.78]). CONCLUSIONS: Interruptions of cART were usually not induced by chemotherapy. The effect of cART interruptions on AIDS-related non-Hodgkin's lymphoma prognosis remains unclear, however, hepatitis C seropositivity emerged-as a predictor of death beyond the well-known international prognostic index score and CD4+ T-cell count. 相似文献
79.
80.
Osih RB Taffé P Rickenbach M Gayet-Ageron A Elzi L Fux C Opravil M Bernasconi E Schmid P Günthard HF Cavassini M;Swiss HIV Cohort Study 《AIDS research and human retroviruses》2010,26(11):1239-1246
Dual-boosted protease inhibitors (DBPI) are an option for salvage therapy for HIV-1 resistant patients. Patients receiving a DBPI in the Swiss HIV Cohort Study between January1996 and March 2007 were studied. Outcomes of interest were viral suppression at 24 weeks. 295 patients (72.5%) were on DBPI for over 6 months. The median duration was 2.2 years. Of 287 patients who had HIV-RNA >400?copies/ml at the start of the regimen, 184 (64.1%) were ever suppressed while on DBPI and 156 (54.4%) were suppressed within 24 weeks. The median time to suppression was 101 days (95% confidence interval 90-125 days). The median number of past regimens was 6 (IQR, 3-8). The main reasons for discontinuing the regimen were patient's wish (48.3%), treatment failure (22.5%), and toxicity (15.8%). Acquisition of HIV through intravenous drug use and the use of lopinavir in combination with saquinavir or atazanavir were associated with an increased likelihood of suppression within 6 months. Patients on DBPI are heavily treatment experienced. Viral suppression within 6 months was achieved in more than half of the patients. There may be a place for DBPI regimens in settings where more expensive alternates are not available. 相似文献